Status: Not yet recruiting
Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 1, single-dose, 2-period crossover study in healthy volunteers to compare the systemic pharmacokinetic (PK) profile of inhaled AERO-002 versus inhaled active comparator product.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: AeroRx Therapeutics Inc.Updated: Sep 3, 2026Locations: 1
Eligibility criteria
Male or female aged 18 to 55 years, inclusive, at the time of informed consent [+9]
Any condition or abnormality (including medical history, clinical laboratory, EC... [+15]